Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations

Simply Wall St.

2024-11-15

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Third Quarter 2024 Results

Key Financial Results

Net loss: US$1.96m (loss narrowed by 68% from 3Q 2023).
US$0.18 loss per share (improved from US$7.22 loss in 3Q 2023).

NasdaqCM:CYCC Earnings and Revenue History November 15th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Cyclacel Pharmaceuticals Earnings Insights

Looking ahead, revenue is forecast to grow 83% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 7.6% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 5 warning signs for Cyclacel Pharmaceuticals that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2483323149"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2483323149\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2483323149?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","is_english":true,"pubTime":"2024-11-15 18:06","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483323149","market":"us","top_or_hot":-1,"title":"Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations","media":"Simply Wall St.","content":"<html><body><h2><a href=\"https://laohu8.com/S/CYCC\">Cyclacel Pharmaceuticals</a> (NASDAQ:CYCC) Third Quarter 2024 Results</h2>\n<h3>Key Financial Results</h3>\n<ul>\n<li>Net loss: US$1.96m (loss narrowed by 68% from 3Q 2023).</li>\n<li>US$0.18 loss per share (improved from US$7.22 loss in 3Q 2023).</li>\n</ul>\n<figure>\n<img height=\"560\" src=\"https://s.yimg.com/uu/api/res/1.2/C2GqiC4AV6cTxALkRkMLWQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/simply_wall_st__316/14fa9ee33162a27d65c069f1da807844\" width=\"821\"/>\n<figcaption>\n  NasdaqCM:CYCC Earnings and Revenue History November 15th 2024\n </figcaption>\n</figure>\n<p><i>All figures shown in the chart above are for the trailing 12 month (TTM) period</i></p>\n<h3><a href=\"https://laohu8.com/S/CYCCP\">Cyclacel Pharmaceuticals</a> Earnings Insights</h3>\n<p> Looking ahead, revenue is forecast to grow 83% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. </p>\n<p><i>Performance of the <strong>American Biotechs industry.</strong></i></p>\n<p> The company's shares are down 7.6% from a week ago. </p>\n<h3>Risk Analysis</h3>\n<p> Before we wrap up, we've discovered <strong>5 warning signs for Cyclacel Pharmaceuticals</strong> that you should be aware of. </p>\n<p><strong>Have feedback on this article? Concerned about the content?</strong> <strong>Get in touch</strong><strong> with us directly.</strong><i> Alternatively, email editorial-team (at) simplywallst.com.</i><br/><br/><i>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</i><br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations\n</h2>\n<h4 class=\"meta\">\n</h4><p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2024-11-15 18:06</span>\n</p>\n</header>\n<article>\n<h2><a href=\"https://laohu8.com/S/CYCC\">Cyclacel Pharmaceuticals</a> (NASDAQ:CYCC) Third Quarter 2024 Results</h2>\n<h3>Key Financial Results</h3>\n<ul>\n<li>Net loss: US$1.96m (loss narrowed by 68% from 3Q 2023).</li>\n<li>US$0.18 loss per share (improved from US$7.22 loss in 3Q 2023).</li>\n</ul>\n<figure>\n<img height=\"560\" src=\"https://s.yimg.com/uu/api/res/1.2/C2GqiC4AV6cTxALkRkMLWQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/simply_wall_st__316/14fa9ee33162a27d65c069f1da807844\" width=\"821\"/>\n<figcaption>\n  NasdaqCM:CYCC Earnings and Revenue History November 15th 2024\n </figcaption>\n</figure>\n<p><i>All figures shown in the chart above are for the trailing 12 month (TTM) period</i></p>\n<h3><a href=\"https://laohu8.com/S/CYCCP\">Cyclacel Pharmaceuticals</a> Earnings Insights</h3>\n<p> Looking ahead, revenue is forecast to grow 83% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. </p>\n<p><i>Performance of the <strong>American Biotechs industry.</strong></i></p>\n<p> The company's shares are down 7.6% from a week ago. </p>\n<h3>Risk Analysis</h3>\n<p> Before we wrap up, we've discovered <strong>5 warning signs for Cyclacel Pharmaceuticals</strong> that you should be aware of. </p>\n<p><strong>Have feedback on this article? Concerned about the content?</strong> <strong>Get in touch</strong><strong> with us directly.</strong><i> Alternatively, email editorial-team (at) simplywallst.com.</i><br/><br/><i>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</i><br/><br/></p>\n<div class=\"bt-text\">\n<p> 來源：<a href=\"https://finance.yahoo.com/news/cyclacel-pharmaceuticals-third-quarter-2024-100653419.html\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CYCCP","symbol_name":"Cyclacel Pharmaceuticals","start_time":0,"source_url":"https://finance.yahoo.com/news/cyclacel-pharmaceuticals-third-quarter-2024-100653419.html","article_id":"2483323149","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483323149","pubTimestamp":1731665213,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"NasdaqCM:CYCC Earnings and Revenue History November 15th 2024. All figures shown in the chart above are for the trailing 12 month  period. Looking ahead, revenue is forecast to grow 83% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.The company's shares are down 7.6% from a week ago.Before we wrap up, we've discovered 5 warning signs for Cyclacel Pharmaceuticals that you should be aware of.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CYCCP":"Cyclacel Pharmaceuticals","CYCC":"Cyclacel Pharmaceuticals"},"translate_title":"Cyclacel Pharmaceuticals 2024年第三季度收益：每股收益超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYCC":0.9,"CYCCP":0.9},"content_text":"Cyclacel Pharmaceuticals (NASDAQ:CYCC) Third Quarter 2024 Results\nKey Financial Results\n\nNet loss: US$1.96m (loss narrowed by 68% from 3Q 2023).\nUS$0.18 loss per share (improved from US$7.22 loss in 3Q 2023).\n\n\n\n\n  NasdaqCM:CYCC Earnings and Revenue History November 15th 2024\n \n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\nCyclacel Pharmaceuticals Earnings Insights\n Looking ahead, revenue is forecast to grow 83% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. \nPerformance of the American Biotechs industry.\n The company's shares are down 7.6% from a week ago. \nRisk Analysis\n Before we wrap up, we've discovered 5 warning signs for Cyclacel Pharmaceuticals that you should be aware of. \nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}